The first principal component was discovered, and the primary HR related genes contributing to it were identified using the expected average contribution value (1/length (variables)*100%) as a criterion. Using the median gene expression value as the crucial value, samples from the IMvigor210 cohort were separated into high and low expression groups, and the log-rank test was performed to examine the difference between the expression level and the immunotherapy prognosis level. To ensure that p < 0.05 was utilized as the screening threshold for module hub genes.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.